Development of plasma cell leukemia in a patient with chronic myeloid leukemia while on treatment with imatinib mesylate

2Citations
Citations of this article
11Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Plasma cell leukemia (PCL) is a rare and an aggressive form of plasma cell dyscrasias. We report a 67-year-old male with PCL which developed while on imatinib mesylate (IM) therapy 38 months after diagnosis of chronic myeloid leukemia (CML). The patient has been treated successfully with bortezomib, melphalan and prednisolone. To our knowledge, only one case of PCL superimposed on Philadelphia positive CML has been reported in the literature and this was before the IM era.

Cite

CITATION STYLE

APA

Maral, S., Bakanay, S., Yikilmaz, A., & Dilek, I. (2018). Development of plasma cell leukemia in a patient with chronic myeloid leukemia while on treatment with imatinib mesylate. Journal of Cancer Research and Therapeutics, 14(6), 1431–1433. https://doi.org/10.4103/0973-1482.192762

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free